PReS-FINAL-2180: Efficacy and safety of tocilizumab (TCZ) in patients with polyarticular-course juvenile idiopathic arthritis (pcJIA): 2-year data from CHERISH.

F De Benedetti,N Ruperto,Zbigniew Zuber,R Cuttica,Ricardo Machado Xavier,I. Calvo,Nadina Rubio,E. Alekseeva,Vyacheslav Chasnyk,Jose Chavez,G. Horneff,Violetta Opoka-Winiarska,Pierre Quartier,Alberto Spindler,Caroline Keane,Kamal N. Bharucha,Jianmei Wang,D Lovell,A. Martini,Hi Brunner

PReS-FINAL-2180: Efficacy and safety of tocilizumab (TCZ) in patients with polyarticular-course juvenile idiopathic arthritis (pcJIA): 2-year data from CHERISH.

2013

Efficacy and safety of TCZ, an IL-6 receptor inhibitor, were previously demonstrated at wk 40 of CHERISH, a phase 3 trial in patients (pts) with pcJIA [1].

Keywords:

Tocilizumab
Arthritis
Rheumatology
Physical therapy
Methotrexate
Medicine
Internal medicine
Juvenile
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations